Peter Evan Harwin - 07 Jun 2023 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Reporting relationship: Director
Issuer ticker: COGT
Reported as of: 07 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2023, 16:37:06 UTC
Prior SEC filing: 10 Jun 2022
Next SEC filing: 16 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Evan D. Kearns, Attorney-in-Fact

Key filing fact

Peter Evan Harwin filed Form 4 for Cogent Biosciences, Inc. (COGT) on 08 Jun 2023.

Key facts

This page summarizes Peter Evan Harwin's Form 4 filing for Cogent Biosciences, Inc. (COGT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2023, 16:37.

Change

Previous filing in this sequence was filed on 10 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COGT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +36,700
Change %
Price: $0.000000
Shares after: 36,700
Date: 07 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 36,700
Exercise price: $11.70
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders.

Footnote F2

Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.